DCPH News and Press, Deciphera Pharmaceuticals Inc. From 02/06/24

2024-02-06 07:01:46 ET More on Deciphera Pharmaceuticals Deciphera: Upside Potential For The Patient Investor Deciphera Pharmaceuticals: Moving The Needle Where It Counts Deciphera forges exclusive distribution deal with Genesis Pharma Seeking Alpha’s ...

– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK ® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 20...

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...

2024-02-05 11:04:02 ET Major earnings expected before the bell on Tuesday include: BP ( BP ) Cummins ( CMI ) DuPont de Nemours ( DD ) Eli Lilly and Co. ( LLY ) Spotify Technology ( SPOT ) Read the full article on Seeking Alpha For furt...

2024-02-05 11:00:36 ET More on Deciphera Pharmaceuticals Deciphera: Upside Potential For The Patient Investor Deciphera Pharmaceuticals: Moving The Needle Where It Counts Deciphera forges exclusive distribution deal with Genesis Pharma Seeking Alpha’s ...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tu...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Gu...

– Median Overall Survival for QINLOCK ® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population – – Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer Patients with Grade 3/4 Treatment-Emergent Advers...

2024-01-09 04:37:11 ET Summary Deciphera Pharmaceuticals has seen a 50% upside with successful phase 3 trial results. DCPH has achieved positive data in a subpopulation of patients with KIT exon 11 primary mutation. The company's pivotal phase 3 study of vimseltinib in TGCT ha...

– Preliminary Unaudited Fourth Quarter 2023 QINLOCK ® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 – – Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and ...